Sara M. Haserlat

12.7k total citations · 2 hit papers
10 papers, 9.8k citations indexed

About

Sara M. Haserlat is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sara M. Haserlat has authored 10 papers receiving a total of 9.8k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sara M. Haserlat's work include Lung Cancer Treatments and Mutations (4 papers), HER2/EGFR in Cancer Research (3 papers) and Genetic factors in colorectal cancer (2 papers). Sara M. Haserlat is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), HER2/EGFR in Cancer Research (3 papers) and Genetic factors in colorectal cancer (2 papers). Sara M. Haserlat collaborates with scholars based in United States, France and Germany. Sara M. Haserlat's co-authors include Daphne W. Bell, Daniel A. Haber, Ross A. Okimoto, Patricia L. Harris, Brian W. Brannigan, Thomas J. Lynch, Jeff Settleman, David C. Christiani, David N. Louis and Sarada Gurubhagavatula and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Sara M. Haserlat

10 papers receiving 9.6k citations

Hit Papers

Activating Mutations in the Epidermal Growth Factor Recep... 2004 2026 2011 2018 2004 2005 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
    2004 8.9k citations Thomas J. Lynch, Daphne W. Bell et al. New England Journal of Medicine profile →
  2. Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
    2005 518 citations Daphne W. Bell, Thomas J. Lynch et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sara M. Haserlat United States 9 7.0k 6.2k 3.7k 2.3k 636 10 9.8k
Patricia L. Harris United States 11 7.5k 1.1× 6.7k 1.1× 4.0k 1.1× 2.3k 1.0× 698 1.1× 15 10.6k
Hidefumi Sasaki Japan 40 7.3k 1.0× 6.4k 1.0× 5.0k 1.4× 2.7k 1.2× 760 1.2× 143 11.9k
Jeffrey C. Lee United States 11 5.8k 0.8× 5.1k 0.8× 4.2k 1.1× 2.2k 0.9× 562 0.9× 14 9.4k
Ross A. Okimoto United States 20 8.1k 1.2× 7.3k 1.2× 4.9k 1.3× 2.7k 1.2× 738 1.2× 33 12.1k
Sean Tracy United States 10 5.6k 0.8× 5.1k 0.8× 3.2k 0.9× 1.9k 0.8× 552 0.9× 20 8.3k
Takayuki Kosaka Japan 32 6.5k 0.9× 5.6k 0.9× 3.8k 1.0× 1.8k 0.8× 624 1.0× 93 9.3k
Katerina Politi United States 38 7.4k 1.1× 7.2k 1.2× 5.5k 1.5× 2.8k 1.2× 630 1.0× 113 12.0k
J. Guillermo Paez United States 8 5.4k 0.8× 4.7k 0.8× 3.6k 1.0× 2.0k 0.9× 534 0.8× 9 8.6k
Paula Herman United States 12 5.5k 0.8× 4.7k 0.8× 3.5k 0.9× 2.0k 0.9× 554 0.9× 14 8.3k
Claire Watkins United Kingdom 21 7.8k 1.1× 7.5k 1.2× 2.9k 0.8× 2.1k 0.9× 393 0.6× 42 11.0k

Countries citing papers authored by Sara M. Haserlat

Since Specialization
Citations

This map shows the geographic impact of Sara M. Haserlat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara M. Haserlat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara M. Haserlat more than expected).

Fields of papers citing papers by Sara M. Haserlat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara M. Haserlat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara M. Haserlat. The network helps show where Sara M. Haserlat may publish in the future.

Co-authorship network of co-authors of Sara M. Haserlat

This figure shows the co-authorship network connecting the top 25 collaborators of Sara M. Haserlat. A scholar is included among the top collaborators of Sara M. Haserlat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara M. Haserlat. Sara M. Haserlat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Draghi, Monia, Jamie L. Schafer, Allison Nelson, et al.. (2019). Abstract 4972: Preclinical development of a first-in-class NKp30xBCMA NK cell engager for the treatment of multiple myeloma. Cancer Research. 79(13_Supplement). 4972–4972. 10 indexed citations
2.
Eskiocak, Uğur, Thomas J. Daly, Allison Nelson, et al.. (2019). Abstract 3239: CTX-5861 mediated SIRPα blockade combines with tumor targeting antibodies, checkpoint blockade and/or CD137 agonism to elicit curative anti-tumor activity in syngeneic mouse models. Cancer Research. 79(13_Supplement). 3239–3239. 2 indexed citations
3.
Zhang, Jianmin, Young‐Han Song, Brian W. Brannigan, et al.. (2009). Prevalence and Functional Analysis of Sequence Variants in the ATR Checkpoint Mediator Claspin. Molecular Cancer Research. 7(9). 1510–1516. 12 indexed citations
4.
Kim, Woo‐Jae, Ross A. Okimoto, Louise E. Purton, et al.. (2008). Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood. 111(9). 4716–4722. 71 indexed citations
5.
Bell, Daphne W., Sang Ho Kim, Andrew K. Godwin, et al.. (2007). Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. International Journal of Cancer. 121(12). 2661–2667. 59 indexed citations
6.
Smolen, Gromoslaw A., Beth Muir, Gayatry Mohapatra, et al.. (2006). Frequent Met Oncogene Amplification in a Brca1/Trp53 Mouse Model of Mammary Tumorigenesis. Cancer Research. 66(7). 3452–3455. 32 indexed citations
7.
Kwak, Eunice L., Janusz Jankowski, Sarah P. Thayer, et al.. (2006). Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas. Clinical Cancer Research. 12(14). 4283–4287. 133 indexed citations
8.
Bell, Daphne W., Thomas J. Lynch, Sara M. Haserlat, et al.. (2005). Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials. Journal of Clinical Oncology. 23(31). 8081–8092. 518 indexed citations breakdown →
9.
Cohen, Ezra E.W., Mark W. Lingen, Leslie E. Martin, et al.. (2005). Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation ofERBB2rather thanEGFR. Clinical Cancer Research. 11(22). 8105–8108. 104 indexed citations
10.
Lynch, Thomas J., Daphne W. Bell, Raffaella Sordella, et al.. (2004). Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine. 350(21). 2129–2139. 8906 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patricia L. Harris Breakdown of academic impact, for papers by Hidefumi Sasaki Breakdown of academic impact, for papers by Jeffrey C. Lee Breakdown of academic impact, for papers by Ross A. Okimoto Breakdown of academic impact, for papers by Sean Tracy Breakdown of academic impact, for papers by Takayuki Kosaka Breakdown of academic impact, for papers by Katerina Politi Breakdown of academic impact, for papers by J. Guillermo Paez Breakdown of academic impact, for papers by Paula Herman Breakdown of academic impact, for papers by Claire Watkins
Rankless by CCL
2026